Acromegaly Pipeline Insight
DelveInsight’s, “Acromegaly - Pipeline Insight, 2023,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Acromegaly pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
- Global coverage
Acromegaly is a disorder that occurs when your body makes too much growth hormone (GH). Produced mainly in the pituitary gland, GH controls the physical growth of the body. In adults, too much of this hormone causes bones, cartilage, body organs, and other tissues to increase in size. Common changes in appearance include enlarged or swollen nose, ears, hands, and feet. Acromegaly is most often diagnosed in middle-aged adults, but symptoms can appear at any age. In children, too much growth hormone causes a condition called gigantism NIH external link rather than acromegaly. Gigantism occurs when excess GH begins before the end of puberty, when children’s growth plates fuse or close. Having too much GH before the growth plates close causes children to grow tall in height.
"Acromegaly - Pipeline Insight, 2023" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acromegaly pipeline landscape is provided which includes the disease overview and Acromegaly treatment guidelines. The assessment part of the report embraces, in depth Acromegaly commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acromegaly collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Acromegaly R&D. The therapies under development are focused on novel approaches to treat/improve Acromegaly.
Acromegaly Emerging Drugs Chapters
This segment of the Acromegaly report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acromegaly Emerging Drugs
IONIS-GHR-LRX: Ionis Pharmaceuticals
IONIS-GHR-LRx is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of the growth hormone receptor (GHr) to decrease the circulating level of insulin-like growth factor-1 (IGF-1). IGF-1 is a hormone primarily produced in the liver that plays an important role in childhood growth and has anabolic effects in adults. Several different diseases result from abnormally low or high levels of IGF-1, or an inappropriate response to this hormone. When produced in excess, IGF-1 results in acromegaly, a chronic, slowly progressing and life-threatening disease. Currently, it is in Phase II stage of development to treat Acromegaly.
Paltusotine: Crinetics Pharmaceuticals
Paltusotine (formerly CRN00808) is an orally available nonpeptide biased agonist that is designed to be highly selective for the somatostatin type 2 receptor. It was designed by the Crinetics discovery team to provide a once daily oral option for patients with acromegaly and neuroendocrine tumors that are currently treated by injected therapies that sell approximately $3.1 billion annually. Non-clinical chronic toxicology studies are complete and no dose limiting toxicity was identified at the maximum feasible doses in rats and dogs. Crinetics previously completed a Phase 1 trial that showed potent suppression of the growth hormone (GH) axis in healthy volunteers, which provided clinical proof-of-concept. In addition, the molecule’s observed plasma half-life of approximately 2 days suggested the potential for paltusotine for once daily oral administration. A subsequent Phase 1 trial showed that paltusotine was 70% orally bioavailable. Paltusotine is an investigational drug currently undergoing two Phase 2 clinical trials for the treatment of acromegaly, the ACROBAT Edge and Evolve trials. Paltusotine has been discovered, characterized, and developed by Crinetics and U.S. patents have been issued covering paltusotine to 2037. Currently, it is in Phase III stage of development to treat Acromegaly.
Further product details are provided in the report……..
Acromegaly: Therapeutic Assessment
This segment of the report provides insights about the different Acromegaly drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Acromegaly
There are approx. 15+ key companies which are developing the therapies for Acromegaly. The companies which have their Acromegaly drug candidates in the most advanced stage, i.e. phase III include, Crinetics Pharmaceuticals.
DelveInsight’s report covers around 15+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Acromegaly pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Acromegaly: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acromegaly therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acromegaly drugs.
Acromegaly Report Insights
- Acromegaly Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Acromegaly Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Acromegaly drugs?
- How many Acromegaly drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acromegaly?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acromegaly therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Acromegaly and their status?
- What are the key designations that have been granted to the emerging drugs?